# Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine

Study · id `cardio:ct-nct01113047` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01113047](<https://clinicaltrials.gov/study/NCT01113047>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01113047

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 347 participants.

## Technical summary

Registry record NCT01113047. Non-randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2010-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 347 participants (enrolled count; ClinicalTrials.gov record NCT01113047, source copy `cardio:ctgov-nct01113047-2013-12-06`, retrieved 2026-10-26)
- Start date: 2010-05 (registry gives no type) (ClinicalTrials.gov record NCT01113047, source copy `cardio:ctgov-nct01113047-2013-12-06`, retrieved 2026-10-26)
- Primary completion: 2010-10 (actual) (ClinicalTrials.gov record NCT01113047, source copy `cardio:ctgov-nct01113047-2013-12-06`, retrieved 2026-10-26)
- Completion: Not reported
- Countries: Germany (ClinicalTrials.gov record NCT01113047, source copy `cardio:ctgov-nct01113047-2013-12-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01113047-2013-12-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
- Acronym: AWESOME
- Condition: Essential Hypertension
- Intervention (Drug): Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ
- Lead sponsor: Novartis
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 8f6fb6c66ae0b5dc6923e0cf374498274ab6234513c331025ed55d1b9cc5b44d
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
